# A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

> **NCT01865747** · PHASE3 · COMPLETED · sponsor: **Exelixis** · enrollment: 658 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib tablets
- **DRUG:** Everolimus (Afinitor) tablets

## Key facts

- **NCT ID:** NCT01865747
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-05-22
- **Final completion:** 2021-01-15
- **Target enrollment:** 658 (ACTUAL)
- **Last updated:** 2021-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01865747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01865747, "A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01865747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*